Why did ALLR's EPS remain stagnant in recent quarters?

The EPS of Allarity Therapeutics (ALLR) remained stagnant in recent quarters due to a combination of factors: 1. **Strategic Financial Management**: Despite the challenges, the company demonstrated resilience in navigating its financial landscape. Significant Improvement in Cash Holdings indicates effective financial management and strategic initiatives undertaken by Allarity Therapeutics to bolster its financial health. 2. **Focus on Stenoparib Development**: The company's focus on developing the therapeutic candidate stenoparib, a dual inhibitor targeting PARP and tankyrases, with ongoing phase 2 clinical trials for ovarian cancer, suggests a strategic allocation of resources that may have impacted short-term earnings but is crucial for long-term growth. In conclusion, the stability of EPS can be attributed to a combination of strategic financial management and a focused approach on developing core therapeutic candidates.